Keywords: Atrial fibrillation; Well-managed VKA; NOACs; Intracranial bleeding; Gastrointestinal bleeding; Elderly;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Anticoagulants; Warfarin resistance; Vitamin K antagonists; Non-vitamin K antagonist oral anticoagulants; NOACs; Dabigatran; Intracardiac thrombus; Thrombosis; Systemic embolism;
Keywords: Novel anticoagulants; NOACs; Coagulopathy of trauma; Reversal agents; Anticoagulants in trauma;
Keywords: AF; atrial fibrillation; CVA; cerebrovascular accident; HCM; hypertrophic cardiomyopathy; LA; left atrium; LVEF; left ventricular ejection fraction; LVOTO; left ventricular outflow tract obstruction; MWT; maximal wall thickness; NOACs; direct oral anticoa
Keywords: OAT; oral anticoagulation therapy; AF; atrial fibrillation; MACE; major adverse cardiac event; INR; international normalized ratio; VKA; vitamin K antagonist; RFCA; radiofrequency catheter ablation; TTR; target therapeutic range; NOACs; new oral anticoagu
Keywords: AF; atrial fibrillation; BMI; body mass index; CI; confidence interval; HDL-C; high-density lipoprotein cholesterol; HR; hazard ratio; INR; international normalized ratio; LDL-C; low-density lipoprotein cholesterol; NOAC; non-vitamin K antagonist oral a
Keywords: NOAC, Non vitamin K Oral Anticoagulant; VKA, Vitamin K Antagonist; ICH, IntraCranial Hemorrhage; PCC, Prothrombin Complex ConcentrateSPAF; NOACs; Reversal agents; Idarucizumab; Adexanet alfa
Factor Xa inhibition and sPESI failure in intermediate-high-risk pulmonary embolism
Keywords: Apixaban; Pulmonary embolism; Intermediate high-risk pulmonary embolism; Thrombolysis; NOACs; sPESI;
Shiga toxin 2a binds antithrombin and heparin, but does not directly activate platelets
Keywords: eHUS; Escherichia coli-induced hemolytic uremic syndrome; Stx; Shiga toxin; EHEC; Enterohemorrhagic Escherichia coli; AT; antithrombin; AKI; acute kidney injury; t-PA antigen; tissue plasminogen activator antigen; PAI-1; t-PA-plasminogen activator inhibit
Nonvitamin K Oral Anticoagulants in Patients With Atrial Fibrillation and Severe Renal Dysfunction
Keywords: Atrial fibrillation; Chronic kidney disease; Nonvitamin K antagonist oral anticoagulants; Fibrilación auricular; Enfermedad renal crónica; Anticoagulantes orales no dependientes de la vitamina K; AF; atrial fibrillation; CKD; chronic kidney disease; CrC
Comparison of Anticoagulant Therapy for Atrial Fibrillation - Novel Oral Anticoagulants Versus Vitamin K Antagonists
Keywords: ACC; American College of Cardiology; ACS; Acute Coronary Syndrome; ACT; Activated Clotting Time; AF; Atrial Fibrillation; AHA; American Heart Association; aPCC; Activated Prothrombin Complex Concentrate; aPTT; Activated Partial Thromboplastin Time; CAD; C
Practical perspectives on the use of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation: A view from the Middle East and North Africa
Keywords: Non-valvular atrial fibrillation; NOACs; Stroke prevention; Middle East and North Africa;
Management and Outcomes of Bleeding Events in Patients in the Emergency Department Taking Warfarin or a Non-Vitamin K Antagonist Oral Anticoagulant
Keywords: anticoagulants; bleeding; NOACs; NVAF; VTE; warfarin;
CYP2C9 and VKORC1 in therapeutic dosing and safety of acenocoumarol treatment: implication for clinical practice in Hungary
Keywords: AC; acenocoumarol; VKA; vitamin K antagonist; NOACs; novel oral anticoagulants; OEP; Hungarian acronym, National Health Insurance Fund of Hungary; INR; International Normalized Ratio; CYP2C9; Cytochrome P450 2C9; VKORC1; Vitamin K Epoxide Reductase Comple
Effectiveness and safety of oral anticoagulation with non-vitamin K antagonists compared to well-managed vitamin K antagonists in naïve patients with non-valvular atrial fibrillation: Propensity score matched cohort study
Keywords: Atrial fibrillation; Real-life; Well-managed VKA; NOACs; Intracranial bleeding; Ischaemic stroke;
Ciraparantag safely and completely reverses the anticoagulant effects of low molecular weight heparin
Keywords: Ciraparantag; PER977; Low molecular weight heparin; Anticoagulant reversal; Whole blood clotting time; NOACs;
Protocol for Cerebral Microbleeds during the Non–Vitamin K Antagonist Oral Anticoagulants or Warfarin Therapy in Stroke Patients with Nonvalvular Atrial Fibrillation (CMB-NOW) Study: Multisite Pilot Trial
Keywords: Acute ischemic stroke; anticoagulant; cerebral microbleeds; MRI; NOACs; warfarin
Ex vivo reversal of the anticoagulant effects of edoxaban
Keywords: aPTT; Activated partial thromboplastin time; Cmax; Maximum plasma concentration; FEIBA; Factor VIII inhibitor bypass activity; FEU; Fibrinogen equivalent units; FX; Factor X; FXa; Factor Xa; LMWH; Low-molecular-weight heparin; NOACs; Novel oral anticoagul
Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy: The PREVAIL Trial
Keywords: atrial fibrillation; left atrial appendage; stroke prevention; LAA; left atrial appendage; NOACs; new oral anticoagulants; NVAF; nonvalvular atrial fibrillation; SE; systemic embolism; TEE; transesophageal echocardiography;